Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinsonian Disorders | 10 | 2023 | 218 | 4.770 |
Why?
|
| Stroke | 20 | 2023 | 254 | 4.070 |
Why?
|
| Brain | 16 | 2023 | 1641 | 3.480 |
Why?
|
| Alzheimer Disease | 13 | 2023 | 2063 | 3.200 |
Why?
|
| Cognitive Dysfunction | 9 | 2023 | 1020 | 2.630 |
Why?
|
| Intracranial Arteriosclerosis | 3 | 2022 | 53 | 2.260 |
Why?
|
| Cerebrovascular Disorders | 4 | 2023 | 132 | 1.830 |
Why?
|
| Aged | 43 | 2023 | 8704 | 1.770 |
Why?
|
| Aged, 80 and over | 28 | 2023 | 4659 | 1.760 |
Why?
|
| Brain Ischemia | 6 | 2020 | 60 | 1.620 |
Why?
|
| Female | 56 | 2023 | 14397 | 1.610 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 43 | 1.550 |
Why?
|
| Male | 54 | 2023 | 14008 | 1.550 |
Why?
|
| Humans | 69 | 2023 | 26025 | 1.430 |
Why?
|
| Dementia | 4 | 2023 | 527 | 1.380 |
Why?
|
| Apolipoprotein E4 | 3 | 2020 | 244 | 1.300 |
Why?
|
| Arteriolosclerosis | 3 | 2023 | 78 | 1.120 |
Why?
|
| Hypertension | 8 | 2023 | 217 | 1.110 |
Why?
|
| Risk Factors | 24 | 2023 | 2243 | 1.100 |
Why?
|
| Atherosclerosis | 3 | 2023 | 49 | 1.090 |
Why?
|
| Aging | 11 | 2023 | 1535 | 1.070 |
Why?
|
| Neuropsychological Tests | 6 | 2023 | 1223 | 1.070 |
Why?
|
| Dementia, Vascular | 2 | 2016 | 45 | 1.050 |
Why?
|
| tau Proteins | 4 | 2023 | 225 | 1.010 |
Why?
|
| Incidence | 15 | 2022 | 713 | 1.010 |
Why?
|
| Disease Progression | 5 | 2021 | 685 | 1.010 |
Why?
|
| Independent Living | 4 | 2023 | 307 | 0.950 |
Why?
|
| TDP-43 Proteinopathies | 2 | 2023 | 109 | 0.940 |
Why?
|
| Stroke Rehabilitation | 2 | 2019 | 8 | 0.940 |
Why?
|
| Cardiovascular Diseases | 10 | 2018 | 333 | 0.910 |
Why?
|
| Limbic Encephalitis | 1 | 2023 | 12 | 0.870 |
Why?
|
| Amyloid beta-Peptides | 4 | 2023 | 318 | 0.860 |
Why?
|
| Motor Disorders | 1 | 2023 | 24 | 0.860 |
Why?
|
| Disabled Persons | 2 | 2023 | 124 | 0.830 |
Why?
|
| Longitudinal Studies | 13 | 2023 | 1340 | 0.810 |
Why?
|
| Iran | 18 | 2021 | 32 | 0.790 |
Why?
|
| Executive Function | 2 | 2015 | 113 | 0.780 |
Why?
|
| Prefrontal Cortex | 3 | 2023 | 143 | 0.740 |
Why?
|
| Exercise | 4 | 2023 | 453 | 0.720 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2021 | 15 | 0.710 |
Why?
|
| Cerebral Hemorrhage | 7 | 2023 | 106 | 0.710 |
Why?
|
| Health Status | 2 | 2021 | 213 | 0.710 |
Why?
|
| Mobility Limitation | 1 | 2021 | 94 | 0.690 |
Why?
|
| White Matter | 1 | 2021 | 141 | 0.680 |
Why?
|
| Child Development | 1 | 2020 | 73 | 0.670 |
Why?
|
| Vision, Ocular | 1 | 2019 | 1 | 0.670 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2021 | 114 | 0.670 |
Why?
|
| Beta Rhythm | 1 | 2019 | 3 | 0.670 |
Why?
|
| Eyeglasses | 1 | 2019 | 3 | 0.670 |
Why?
|
| Mental Health | 1 | 2021 | 105 | 0.670 |
Why?
|
| Agnosia | 1 | 2019 | 9 | 0.660 |
Why?
|
| Cohort Studies | 14 | 2022 | 1823 | 0.660 |
Why?
|
| Visual Perception | 1 | 2019 | 35 | 0.660 |
Why?
|
| Blood Pressure | 2 | 2020 | 194 | 0.660 |
Why?
|
| Brain Infarction | 1 | 2020 | 74 | 0.650 |
Why?
|
| Gait | 1 | 2023 | 408 | 0.640 |
Why?
|
| Motor Activity | 3 | 2019 | 318 | 0.640 |
Why?
|
| Cognition | 4 | 2023 | 1290 | 0.620 |
Why?
|
| Sex Characteristics | 1 | 2018 | 118 | 0.580 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2017 | 8 | 0.580 |
Why?
|
| Upper Extremity | 1 | 2017 | 56 | 0.560 |
Why?
|
| Age Factors | 7 | 2021 | 744 | 0.550 |
Why?
|
| Middle Aged | 29 | 2023 | 8507 | 0.550 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2015 | 26 | 0.510 |
Why?
|
| Autopsy | 4 | 2021 | 338 | 0.510 |
Why?
|
| Aspirin | 1 | 2015 | 77 | 0.490 |
Why?
|
| Triglycerides | 3 | 2022 | 40 | 0.480 |
Why?
|
| Case-Control Studies | 11 | 2023 | 550 | 0.440 |
Why?
|
| Metabolic Syndrome | 4 | 2018 | 55 | 0.430 |
Why?
|
| Parkinson Disease | 4 | 2023 | 826 | 0.420 |
Why?
|
| Receptors, Estrogen | 2 | 2023 | 57 | 0.420 |
Why?
|
| Canada | 4 | 2015 | 49 | 0.360 |
Why?
|
| Adult | 18 | 2023 | 7363 | 0.340 |
Why?
|
| Obesity | 4 | 2019 | 277 | 0.340 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 254 | 0.330 |
Why?
|
| Prospective Studies | 9 | 2023 | 1659 | 0.330 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 1712 | 0.320 |
Why?
|
| Time Factors | 4 | 2019 | 1365 | 0.320 |
Why?
|
| Waist Circumference | 4 | 2019 | 32 | 0.310 |
Why?
|
| Cognition Disorders | 3 | 2016 | 986 | 0.310 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 373 | 0.290 |
Why?
|
| Recovery of Function | 2 | 2019 | 279 | 0.280 |
Why?
|
| Disability Evaluation | 2 | 2019 | 287 | 0.270 |
Why?
|
| Treatment Outcome | 6 | 2021 | 3292 | 0.270 |
Why?
|
| Language | 1 | 2006 | 63 | 0.260 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 522 | 0.250 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 326 | 0.250 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 856 | 0.250 |
Why?
|
| Neurofibrillary Tangles | 2 | 2023 | 191 | 0.250 |
Why?
|
| Hospitalization | 1 | 2007 | 293 | 0.240 |
Why?
|
| Waist-Hip Ratio | 5 | 2019 | 12 | 0.240 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1068 | 0.240 |
Why?
|
| Risk Assessment | 4 | 2021 | 622 | 0.220 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2023 | 18 | 0.220 |
Why?
|
| Binge Drinking | 1 | 2023 | 7 | 0.220 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2023 | 23 | 0.210 |
Why?
|
| RNA | 1 | 2023 | 33 | 0.210 |
Why?
|
| Smoking | 3 | 2020 | 169 | 0.210 |
Why?
|
| Cerebrum | 1 | 2023 | 11 | 0.210 |
Why?
|
| Opium | 1 | 2022 | 1 | 0.210 |
Why?
|
| Hand Strength | 1 | 2023 | 56 | 0.210 |
Why?
|
| Cholesterol | 1 | 2022 | 43 | 0.210 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 53 | 0.200 |
Why?
|
| Spinal Cord | 1 | 2022 | 82 | 0.200 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2021 | 1 | 0.200 |
Why?
|
| Migraine Disorders | 1 | 2021 | 9 | 0.190 |
Why?
|
| Motor Cortex | 1 | 2021 | 14 | 0.190 |
Why?
|
| Life Style | 2 | 2020 | 189 | 0.190 |
Why?
|
| Ontario | 1 | 2021 | 15 | 0.190 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 126 | 0.190 |
Why?
|
| Potassium | 1 | 2021 | 63 | 0.180 |
Why?
|
| Sodium | 1 | 2021 | 60 | 0.180 |
Why?
|
| Nerve Block | 1 | 2021 | 63 | 0.180 |
Why?
|
| Sex Factors | 2 | 2020 | 442 | 0.180 |
Why?
|
| Peptides | 1 | 2021 | 97 | 0.180 |
Why?
|
| Walking | 1 | 2023 | 258 | 0.180 |
Why?
|
| Movement Disorders | 1 | 2021 | 89 | 0.170 |
Why?
|
| Biomarkers | 2 | 2020 | 549 | 0.170 |
Why?
|
| Psychomotor Performance | 1 | 2021 | 202 | 0.170 |
Why?
|
| Residence Characteristics | 2 | 2012 | 210 | 0.160 |
Why?
|
| Functional Laterality | 1 | 2019 | 62 | 0.160 |
Why?
|
| Depression | 1 | 2023 | 410 | 0.160 |
Why?
|
| Linear Models | 1 | 2020 | 240 | 0.160 |
Why?
|
| Noncommunicable Diseases | 1 | 2018 | 2 | 0.160 |
Why?
|
| Heredity | 1 | 2018 | 6 | 0.160 |
Why?
|
| Apolipoproteins E | 1 | 2020 | 250 | 0.160 |
Why?
|
| Pedigree | 1 | 2018 | 55 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 277 | 0.160 |
Why?
|
| Glycogen Storage Disease Type III | 1 | 2018 | 1 | 0.150 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 133 | 0.150 |
Why?
|
| Glycogen | 1 | 2018 | 16 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2019 | 378 | 0.150 |
Why?
|
| ROC Curve | 4 | 2022 | 132 | 0.150 |
Why?
|
| Milk | 1 | 2017 | 14 | 0.150 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 12 | 0.150 |
Why?
|
| CADASIL | 1 | 2017 | 1 | 0.150 |
Why?
|
| Research Design | 1 | 2018 | 181 | 0.140 |
Why?
|
| Menopause | 1 | 2018 | 94 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 104 | 0.140 |
Why?
|
| Genotype | 1 | 2018 | 335 | 0.140 |
Why?
|
| Chicago | 1 | 2020 | 844 | 0.140 |
Why?
|
| alpha-Synuclein | 1 | 2018 | 121 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2017 | 202 | 0.140 |
Why?
|
| Vasodilation | 1 | 2016 | 3 | 0.140 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2016 | 5 | 0.140 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2016 | 5 | 0.140 |
Why?
|
| Mutation | 1 | 2018 | 311 | 0.140 |
Why?
|
| Child | 1 | 2020 | 1228 | 0.130 |
Why?
|
| Methamphetamine | 1 | 2016 | 21 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 35 | 0.130 |
Why?
|
| Neuropathology | 1 | 2016 | 83 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 457 | 0.130 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 42 | 0.130 |
Why?
|
| Tropanes | 1 | 2015 | 1 | 0.130 |
Why?
|
| Organotechnetium Compounds | 1 | 2015 | 8 | 0.130 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 23 | 0.130 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 13 | 0.130 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 41 | 0.130 |
Why?
|
| Prediabetic State | 1 | 2014 | 3 | 0.120 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 78 | 0.120 |
Why?
|
| Heart Rate | 1 | 2014 | 103 | 0.110 |
Why?
|
| Incidental Findings | 1 | 2014 | 13 | 0.110 |
Why?
|
| Body Mass Index | 3 | 2023 | 412 | 0.110 |
Why?
|
| Memory | 1 | 2015 | 300 | 0.110 |
Why?
|
| Interviews as Topic | 2 | 2019 | 123 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 173 | 0.100 |
Why?
|
| Rural Population | 1 | 2012 | 23 | 0.100 |
Why?
|
| Quality of Life | 1 | 2016 | 609 | 0.090 |
Why?
|
| Urban Population | 1 | 2012 | 143 | 0.090 |
Why?
|
| Phenotype | 2 | 2023 | 290 | 0.090 |
Why?
|
| Alcohol Drinking | 2 | 2022 | 68 | 0.080 |
Why?
|
| Logistic Models | 1 | 2010 | 362 | 0.080 |
Why?
|
| Efferent Pathways | 1 | 2008 | 1 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 670 | 0.080 |
Why?
|
| Neural Conduction | 1 | 2008 | 8 | 0.080 |
Why?
|
| Action Potentials | 1 | 2008 | 85 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2022 | 3297 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 81 | 0.070 |
Why?
|
| Skin | 1 | 2008 | 103 | 0.070 |
Why?
|
| Comorbidity | 2 | 2021 | 466 | 0.070 |
Why?
|
| Middle East | 2 | 2017 | 5 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 930 | 0.070 |
Why?
|
| Developing Countries | 2 | 2018 | 12 | 0.070 |
Why?
|
| Diabetes Complications | 2 | 2017 | 56 | 0.070 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 186 | 0.070 |
Why?
|
| Europe | 2 | 2016 | 65 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2017 | 260 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 215 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 750 | 0.060 |
Why?
|
| Angina, Unstable | 2 | 2014 | 9 | 0.060 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2014 | 14 | 0.060 |
Why?
|
| Prevalence | 2 | 2016 | 433 | 0.060 |
Why?
|
| Infarction | 1 | 2023 | 30 | 0.050 |
Why?
|
| Adaptor Protein Complex 1 | 1 | 2023 | 6 | 0.050 |
Why?
|
| Adaptor Protein Complex beta Subunits | 1 | 2023 | 6 | 0.050 |
Why?
|
| Olfactory Bulb | 1 | 2023 | 18 | 0.050 |
Why?
|
| Proteome | 1 | 2023 | 41 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2014 | 134 | 0.050 |
Why?
|
| Health Surveys | 2 | 2013 | 84 | 0.050 |
Why?
|
| Muscle Spasticity | 1 | 2021 | 4 | 0.050 |
Why?
|
| Triamcinolone | 1 | 2021 | 4 | 0.050 |
Why?
|
| Lewy Bodies | 1 | 2023 | 193 | 0.050 |
Why?
|
| Lidocaine | 1 | 2021 | 24 | 0.050 |
Why?
|
| Headache | 1 | 2021 | 30 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2021 | 38 | 0.050 |
Why?
|
| Young Adult | 2 | 2018 | 1853 | 0.050 |
Why?
|
| Potassium, Dietary | 1 | 2021 | 1 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 111 | 0.050 |
Why?
|
| Sodium, Dietary | 1 | 2021 | 4 | 0.050 |
Why?
|
| Causality | 1 | 2021 | 52 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 51 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2021 | 253 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2022 | 212 | 0.040 |
Why?
|
| Sleep | 1 | 2023 | 255 | 0.040 |
Why?
|
| Waist-Height Ratio | 1 | 2019 | 5 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2019 | 24 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 14 | 0.040 |
Why?
|
| Anthropometry | 1 | 2019 | 35 | 0.040 |
Why?
|
| Adiposity | 1 | 2019 | 38 | 0.040 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 16 | 0.040 |
Why?
|
| Physical Examination | 1 | 2019 | 112 | 0.040 |
Why?
|
| Glycogen Debranching Enzyme System | 1 | 2018 | 1 | 0.040 |
Why?
|
| Developed Countries | 1 | 2018 | 3 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 68 | 0.040 |
Why?
|
| Mediterranean Region | 1 | 2017 | 3 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 38 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 235 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 91 | 0.040 |
Why?
|
| Poverty | 1 | 2018 | 96 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2018 | 65 | 0.040 |
Why?
|
| Microvessels | 1 | 2017 | 14 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 99 | 0.040 |
Why?
|
| Nitroglycerin | 1 | 2016 | 1 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 2016 | 4 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 15 | 0.030 |
Why?
|
| Overweight | 1 | 2017 | 67 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 252 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2016 | 2 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 2016 | 2 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 10 | 0.030 |
Why?
|
| Africa | 1 | 2016 | 9 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 28 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 37 | 0.030 |
Why?
|
| International Cooperation | 1 | 2016 | 22 | 0.030 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 19 | 0.030 |
Why?
|
| China | 1 | 2016 | 50 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 295 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 199 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 71 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 23 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2016 | 75 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2016 | 72 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 204 | 0.030 |
Why?
|
| United States | 1 | 2021 | 1981 | 0.030 |
Why?
|
| Health Behavior | 1 | 2016 | 154 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 358 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 290 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 342 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 132 | 0.030 |
Why?
|
| Diet | 1 | 2014 | 169 | 0.030 |
Why?
|
| Rural Health | 1 | 2013 | 8 | 0.030 |
Why?
|
| Urban Health | 1 | 2013 | 21 | 0.030 |
Why?
|
| Adolescent | 1 | 2018 | 2064 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 14 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 90 | 0.020 |
Why?
|
| Public Health | 1 | 2012 | 63 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 184 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 122 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 321 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 186 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 3389 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2008 | 48 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2008 | 94 | 0.020 |
Why?
|
| Hand | 1 | 2008 | 35 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2008 | 222 | 0.020 |
Why?
|